Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week open-label randomized study of fesoterodine in children and adolescents with neurogenic detrusor overactivity
2010-022475-55Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxybutynin in detrusor hyperreflexia (DH) and neurogenic bladder (2 arms), sponsored by Pfizer. Primary endpoint: Maximum cystometric bladder capacity. Started Apr 2012; status: completed.
02
Drugs
oxybutynin
03
Conditions
detrusor hyperreflexia (DH)neurogenic bladder
Beyond the preview
Go deeper on 2010-022475-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022475-55.